Use of dual H3/M2 antagonists in the treatment of cognition deficit disorders
US6906081B2 · kind B2 · utility
6Cited by
19References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 6, 2002 |
| Grant date | Jun 14, 2005 |
| Priority date | — |
| Expiry date | May 11, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to a method of treating cognition deficit disorders comprising administering to a mammal in need of such treatment an effective amount of a dual histamine H3 receptor antagonist/m2 muscarinic antagonist, or a combination of a histamine H3 receptor antagonist and a m2 muscarinic antagonist.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.